Five years after CONSORT-AI, not much has changed: a call to action for artificial intelligence research in oncology

Since its introduction in 1996, the Consolidated Standards of Reporting Trials (CONSORT) statement has been widely used to facilitate transparent reporting of randomised controlled trials (RCTs), including those in oncology.1 Due to the unique methodological and implementation challenges associated with artificial intelligence (AI)-based interventions, the CONSORT group subsequently released the CONSORT-AI extension in 2020.2 This extension introduced 14 AI-specific items to strengthen the clarity, reproducibility and reliability of trials involving AI tools.